| Literature DB >> 28597127 |
Anna Karin Hedström1, Michail Katsoulis2, Ola Hössjer3, Izaura L Bomfim4, Annette Oturai5, Helle Bach Sondergaard5, Finn Sellebjerg5, Henrik Ullum6, Lise Wegner Thørner6, Marte Wendel Gustavsen7,8, Hanne F Harbo7,8, Dragana Obradovic9, Milena A Gianfrancesco10, Lisa F Barcellos10, Catherine A Schaefer11, Jan Hillert12, Ingrid Kockum12, Tomas Olsson12, Lars Alfredsson13.
Abstract
Interactions between environment and genetics may contribute to multiple sclerosis (MS) development. We investigated whether the previously observed interaction between smoking and HLA genotype in the Swedish population could be replicated, refined and extended to include other populations. We used six independent case-control studies from five different countries (Sweden, Denmark, Norway, Serbia, United States). A pooled analysis was performed for replication of previous observations (7190 cases, 8876 controls). Refined detailed analyses were carried out by combining the genetically similar populations from the Nordic studies (6265 cases, 8401 controls). In both the pooled analyses and in the combined Nordic material, interactions were observed between HLA-DRB*15 and absence of HLA-A*02 and between smoking and each of the genetic risk factors. Two way interactions were observed between each combination of the three variables, invariant over categories of the third. Further, there was also a three way interaction between the risk factors. The difference in MS risk between the extremes was considerable; smokers carrying HLA-DRB1*15 and lacking HLA-A*02 had a 13-fold increased risk compared with never smokers without these genetic risk factors (OR 12.7, 95% CI 10.8-14.9). The risk of MS associated with HLA genotypes is strongly influenced by smoking status and vice versa. Since the function of HLA molecules is to present peptide antigens to T cells, the demonstrated interactions strongly suggest that smoking alters MS risk through actions on adaptive immunity.Entities:
Keywords: Gene–environment interaction; HLA; Multiple sclerosis; Smoking
Mesh:
Substances:
Year: 2017 PMID: 28597127 PMCID: PMC5680370 DOI: 10.1007/s10654-017-0250-2
Source DB: PubMed Journal: Eur J Epidemiol ISSN: 0393-2990 Impact factor: 8.082
Flow chart, Nordic studies
| Study | Included in the study | Data on smoking, birth year, and gender. No overlap EIMS/GEMS | Nordic origin | Past smokers excluded | HLA genotype available. Dataset for analysis |
|---|---|---|---|---|---|
| EIMS | |||||
| Cases | 2488 | 2488 | 2027 | 1569 | 1308 |
| Controls | 5433 | 5433 | 4243 | 3379 | 1858 |
| GEMS | |||||
| Cases | 6156 | 6085 | 5520 | 4264 | 3272 |
| Controls | 5408 | 5357 | 4568 | 3762 | 2382 |
| Danish study | |||||
| Cases | 2048 | 2048 | 1832 | 1520 | 1474 |
| Controls | 4546 | 4541 | 4277 | 3618 | 3469 |
| Norwegian study | |||||
| Cases | 332 | 316 | 316 | 278 | 211 |
| Controls | 773 | 756 | 748 | 702 | 692 |
Replication and extension of previous results
| DR15+ | A2− | ca/coa | OR (95% CI)b |
| AP |
|---|---|---|---|---|---|
| OR with 95% CI of developing MS for subjects categorized by HLA-DRB1*15 and HLA-A*02. Attributable proportion due to interaction between HLA-DRB1*15 and HLA-A*02 | |||||
| − | − | 1232/3354 | 1.0 (–) | 1.0 (–) | |
| − | + | 1734/2881 | 1.6 (1.4–1.8) | <0.0001 | |
| + | − | 1864/1457 | 3.6 (3.2–4.0) | <0.0001 | |
| + | + | 2360/1184 | 5.7 (5.2–6.3) | <0.0001 | 0.34 (0.29–0.39), |
All studies pooled together
aNumber of exposed cases and controls
bAdjusted for age, gender, and smoking
cAdjusted for age, gender, and HLA-DRB1*15
dAdjusted for age, gender, and HLA-A*02
Two way interactions on the additive scale between HLA-DRB1*15 and absence of HLA-A*02, between absence of HLA-A*02 and smoking, and between HLA-DRB1*15 and smoking
| DR15 | A2− | Smoking | APa | APb | APc | APd | APe | APf |
|---|---|---|---|---|---|---|---|---|
| x | x | 0.4 (0.2–0.5) | 0.2 (0.04–0.3) | 0.3 (0.1–0.4) | 0.5 (0.2–0.7) | −0.3 (−1 to 0.4) | 0.5 (0.3–0.7) | |
| x | x | 0.3 (0.1–0.5) | 0.2 (0.008–0.3) | 0.2 (0.005–0.3) | 0.3 (0.0–0.7) | 0.2 (−0.09 to 0.6) | 0.0 (−0.3 to 0.3) | |
| x | x | 0.3 (0.08–0.4) | 0.2 (0.06–0.3) | 0.4 (0.3–0.5) | 0.3 (0.05–0.6) | 0.4 (0.2–0.7) | 0.4 (0.1–0.6) |
Attributable proportion due to interaction with 95% CI
aEIMS, study
bGEMS
cDanish study
dNorwegian study
eSerbian study
fAmerican study
Combined study using participants of Nordic origin
| DR15+ | A2− | ca/coa | OR (95% CI)b |
| AP |
|---|---|---|---|---|---|
|
| |||||
| Total | |||||
| − | − | 991/3192 | 1.0 (–) | ||
| − | + | 1428/2639 | 1.8 (1.6–1.9) | <0.0001 | |
| + | − | 1732/1439 | 3.9 (3.5–4.3) | <0.0001 | |
| + | + | 2114/1131 | 6.1 (5.5–6.8) | <0.0001 | 0.2 (0.1–0.4), |
aNumber of exposed cases and controls
bAdjusted for age, gender, smoking, and study
cAdjusted for age, gender, and study
dAdjusted for age, gender, HLA-DRB1*15, and study
eAdjusted for age, gender, HLA-A*02, and study
Combined two- and three-way interaction on the additive scale between HLA-DRB1*15, absence of HLA-A*02, and smoking
| Study | TotAP3 | TotRERI3 | TotSI3 |
|---|---|---|---|
| EIMS | 0.6 (0.4–0.7) | 6.7 (3.0–10.3) | 2.9 (1.9–4.4) |
| GEMS | 0.3 (0.2–0.5) | 3.5 (1.3–5.7) | 1.6 (1.2–2.1) |
| Danish study | 0.6 (0.5–0.7) | 10.8 (6.5–15.0) | 2.8 (2.1–3.7) |
| Norwegian study | 0.7 (0.5–0.9) | 12.6 (1.1–24.2) | 3.5 (1.6–8.0) |
| Nordic studies combined | 0.5 (0.46–0.61) | 6.8 (5.0–8.5) | 2.4 (2.0–2.8) |
Total attributable proportion due to interaction, relative excess risk and synergy index due to interaction, with 95% CI
Three way interaction on the additive scale between HLA-DRB1*15, absence of HLA-A*02 and smoking
| Study | AP3 | RERI3 | SI3 |
|---|---|---|---|
| EIMS | 0.4 (0.1–0.6) | 4.4 (0.3–8.4) | 1.7 (1.1–2.8) |
| GEMS | −0.02 (−0.3 to 0.3) | −0.2 (−3.1 to 2.6) | 1.0 (0.7–1.3) |
| Danish study | 0.09 (0.2–0.3) | 1.6 (−3.4 to 6.5) | 1.1 (0.8–1.5) |
| Norwegian study | 0.2 (−0.3 to 0.7) | 4.1 (−7.9 to 16.1) | 1.3 (0.6–2.8) |
| Nordic studies combined | 0.2 (0.002–0.3) | 1.9 (−0.16 to 3.92) | 1.2 (1.0–1.4) |
Total attributable proportion due to interaction, relative excess risk and synergy index due to interaction, with 95% CI